Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients

NCT00419926 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

313

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplantation

Interventions

DRUG: Enteric-coated mycophenolate sodium (Myfortic)
DRUG: Cyclosporine (Neoral)
DRUG: Prednisone

Sponsor

Novartis